Innovent’s trial of picankibart for ulcerative colitis meets primary endpoint
The primary endpoint was clinical remission at week 12, with secondary endpoints of clinical response and endoscopic remission.
17 October 2024
17 October 2024
The primary endpoint was clinical remission at week 12, with secondary endpoints of clinical response and endoscopic remission.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.